Interestingly, high levels of JAM-A tended to associate with longer survival in patients with AA in the OUH astrocytoma cohort, while this was not the case in RSD glioma cohort; this could be due to the uneven distribution of IDH mutated tumors, as most AAs in the RSD cohort had mutations in IDH, while most AAs in OUH cohort were IDH wildtype. The gene discussed is IDH1; the disease is astrocytoma (excluding glioblastoma).